Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer

Expert Opinion on Biological Therapy

Volumn 16, Issue 6, 2016, Pages 747-758

  Losanno, Tania ^a   Rossi, Antonio ^b   Maione, Paolo ^b   Napolitano, Alba ^b   Gridelli, Cesare ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

Author keywords

bevacizumab; cetuximab; EGFR; monoclonal antibodies; necitumumab; NSCLC; ramucirumab; VEGF; VEGFR

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEMCITABINE; NECITUMUMAB; RAMUCIRUMAB; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; DRUG APPROVAL; GENE MUTATION; HUMAN; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; METABOLISM; PROCEDURES;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; BEVACIZUMAB; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84961392447     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2016.1163333     Document Type: Review

References (50)

1. L.A.Torre, F.Bray, R.L.Siegel, et al. Global Cancer Statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi:10.3322/caac.21262.
2. A.Sandler, R.Gray, M.C.Perry, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–2550. doi:10.1056/NEJMoa061884.• Bevacizumab as the first antiangiogenic mAb with a relevant impact on clinical practice.
3. M.Reck, J.von Pawel, P.Zatloukal, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol. 2009;27:1227–1234. doi:10.1200/JCO.2007.14.5466.• Bevacizumab as the first antiangiogenic mAb with a relevant impact on clinical practice.
4. C.Zhou, Y.-L.Wu, G.Chen, et al. BEYOND: A randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol. 2015;33:2197–2204. doi:10.1200/JCO.2014.59.4424.
5. R.Pirker, J.R.Pereira, A.Szczesna, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009;373:1525–1531. doi:10.1016/S0140-6736(09)60569-9.
6. T.J.Lynch, T.Patel, L.Dreisbach, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the ramdomized multicenter phase III trial BMS099. J Clin Oncol. 2010;28:911–917. doi:10.1200/JCO.2009.21.9618.
7. G.V.Scagliotti, G.Selvaggi, S.Novello, et al. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res. 2004;10:4227S–4232S, suppl 12.
8. N.Normanno, C.Bianco, L.Strizzi, et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets. 2005;6:243–257.
9. J.Mendelsohn Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002;20:1S–13S.
10. R.A.Clynes, T.L.Towers, L.G.Presta, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443–446. doi:10.1038/74704.
11. F.Robert, G.Blumenschein, R.S.Herbst, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:8786–8793. doi:10.1200/JCO.2005.03.1997.
12. C.A.Butts, D.Bodkin, E.L.Middleman, et al. Randomized phase II study of gemcitabine/platinum with or without cetuximab as first-line therapy for patients with advanced/metastatic non-small-cell lung cancer (NSCLC). J Clin Oncol. 2007;25:5777–5784. doi:10.1200/JCO.2007.13.0856.
13. C.D.Thienelt, B.P.A.Bunn, N.Hanna, et al. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005;23:8786–8793. doi:10.1200/JCO.2005.03.1997.
14. R.S.Herbst, K.Kelly, K.Chansky, et al. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small cell lung cancer: Southwest Oncology Group study S0342. Journal of Clinical Oncology. 2010;28(31):4747–4754. doi:10.1200/JCO.2009.27.9356.
15. R.Pirker, J.R.Pereira, J.von Pawel, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012;13:33–42. doi:10.1016/S1470-2045(12)70140-7.
16. J.-Y.Douillard, R.Pirker, K.J.O’Byrne, et al. Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9:717–724. doi:10.1097/JTO.0000000000000141.
17. European Medicines Agency refusal cetuximab authorization in NSCLC [Internet]. [cited 2016 Feb13]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000558/WC500070798.pdf
18. D.F.Heigener, J.R.Pereira, E.Felip, et al. Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small-cell lung cancer: randomized non-comparative phase IIIb NEXT trial. Targ Oncol. 2015;10:255–265. doi:10.1007/s11523-014-0336-7.
19. E.S.Kim, J.Moon, R.S.Herbst, et al. Phase II trial of carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab and bevacizumab in advanced non-squamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol. 2013;8(12):1519–1528. doi:10.1097/JTO.0000000000000009.
20. M.W.Redman, J.J.Crowley, R.S.Herbst, et al. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res. 2012;18(15):4004–4012. doi:10.1158/1078-0432.CCR-12-0167.
21. R.S.Herbst, M.W.Redman, E.S.Kim et al. A randomized, phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/ bevacizumab with or without concurrent cetuximab in patients with advanced Non-Small Cell Lung Cancer (NSCLC): SWOG S0819. IASLC - 16th World Conference on Lung Cancer, September6–9, 2015.
22. N.H.Hanna, S.E.Dahlberg, J.M.Kolesar, et al. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small-cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: an Eastern Cooperative Oncology Group (ECOG) study (E4508). Cancer. 2015;121:2253–2261. doi:10.1002/cncr.29308.
23. L.Paz-Ares, J.Mezger, T.E.Ciuleanu, et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, ramdomised, controlled phase 3 study. Lancet Oncol. 2015;16:328–337. doi:10.1016/S1470-2045(15)70046-X.
24. N.Thatcher, F.R.Hirsch, A.V.Luft, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2015;16:763–774. doi:10.1016/S1470-2045(15)00021-2.•• Necitumumab as the first mAb approved for squamous histology. Till now, this histotype was the one with no improvement in any outcome, but necitumumab and immunotherapy are changing the prognosis of squamous NSCLC.
25. U.S. Food and Drug Administration approved necitumumab. Necitumumab approval [Internet]. [cited 2016 Feb11]. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm474278.htm•• Necitumumab as the first mAb approved for squamous histology. Till now this histotype was the one with no improvement in any outcome, but necitumumab and immunotherapy are changing the prognosis of squamous NSCLC.
26. T.H.Adair, J.P.Montani. Angiogenesis. San Rafael, CA: Morgan & Claypool Life Sciences; 2010.
27. N.Ferrara, R.S.Kerbel. Angiogenesis as a therapeutic target. Nature. 2005;438:967–974. doi:10.1038/nature04483.
28. D.J.Hicklin, L.M.Ellis. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–1027. doi:10.1200/JCO.2005.06.081.
29. D.H.Johnson, L.Fehrenbacher, W.F.Novotny, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–2191. doi:10.1200/JCO.2004.11.022.
30. V.Hirsh. Emerging safety data for bevacizumab in advanced non-small-cell lung cancer. Clinical Lung Cancer. 2008;9:S62–S70. (suppl. 2). doi:10.3816/CLC.2008.s.010.
31. J.D.Patel, M.A.Socinski, E.B.Garon, et al. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31:4349–4357. doi:10.1200/JCO.2012.47.9626.
32. R.G.Zinner, C.K.Obasaju, D.R.Spigel, et al. Pronounce: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients with advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015;10:134–142. doi:10.1097/JTO.0000000000000366.
33. F.Barlesi, A.Scherpereel, A.Rittmeyer, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31:3004–3011. doi:10.1200/JCO.2012.42.3749.
34. F.Barlesi, A.Scherpereel, V.Gorbunova, et al. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous non-small-cell lung cancer: update survival analysis of the AVAPERL (MO22089) randomized phase III trial. Annals of Oncology. 2014;25:1044–1052. doi:10.1093/annonc/mdu098.
35. R.S.Herbst, R.Ansari, F.Bustin, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double- blind, placebo-controlled, phase 3 trial. Lancet. 2011;377:1846–1854. doi:10.1016/S0140-6736(11)60545-X.
36. B.E.Johnson, F.Kabbinavar, L.Fehrenbacher, et al. Atlas: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013;31:3926–3934. doi:10.1200/JCO.2012.47.3983.
37. O.Gautschi, N.Mach, S.I.Rothschild, et al. Bevacizumab, pemetrexed, and cisplatin, or bevacizumab and erlotinib for patients with advanced non-small-cell lung cancer stratified by epidermal growth factor receptor mutation: phase II trial SAKK19/09. Clin Lung Cancer. 2015;16:358–365. doi:10.1016/j.cllc.2015.02.007.
38. R.A.Stahel, U.Dafni, O.Gautschi, et al. A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial. Ann Oncol. 2015;26(suppl 6):abstr 3BA. doi:10.1093/annonc/mdv383.•• Erlotinib and bevacizumab in European patients with advanced NSCLC with T790M mutation. Great expectations are in this association especially in T790M+ patients, to overcome resistance to anti-EGFR therapy.
39. T.Seto, T.Kato, M.Nishio, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15:1236–1244. doi:10.1016/S1470-2045(14)70381-X.• Erlotinib and bevacizumab as first-line therapy in Japanese patients with non-squamous EGFR-mut NSCLC.
40. R.Ramlau, V.Gorbunova, T.E.Ciuleanu, et al. Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non–small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol. 2012;30:3640–3647. doi:10.1200/JCO.2012.42.6932.
41. H.Wilke, E.V.Cutsem, S.C.Oh, et al. RAINBOW: a global, phase 3, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy IMCL CP12–0922 (I4T-IE-JVBE). J Clin Oncol. 2014;32(suppl 3):abstr LBA7. doi:10.1200/JCO.2013.54.6911.
42. C.S.Fuchs, J.Tomasek, C.J.Yong, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–39. doi:10.1016/S0140-6736(13)61612-8.
43. N.R.Smith, D.Baker, N.H.James, et al. Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers. Clin Cancer Res. 2010;16:3548–3561. doi:10.1158/1078-0432.CCR-09-2797.
44. E.B.Garon, T.E.Ciuleanu, O.Arrieta, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384:665–673. doi:10.1016/S0140-6736(14)60845-X.• Ramucirumab for the possibility to associate a novel antiangiogenic drug to chemotherapy with docetaxel in second-line setting.
45. E.S.Kim, M.Neubauer, A.Cohn, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol. 2013;14:1326–1336. doi:10.1016/S1470-2045(13)70473-X.
46. G.A.Masters, S.Temin, C.G.Azzoli, et al. Systemic therapy for Stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33:3488–3515. doi:10.1200/JCO.2015.62.1342.
47. NCCN Clinical Practice Guidelines. Version 2.2016. [updated 2015 Nov23; cited 2015 Dec 7]. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
48. L.Paz Ares, F.De Marinis, M.Dediu, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012;13:247–255. doi:10.1016/S1470-2045(12)70063-3.
49. J.Brahmer, K.L.Reckamp, P.Baas, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373:123–135. doi:10.1056/NEJMoa1504627.•• Anti PD-1/PD-L1 as a valid therapeutic option in second-line setting, especially in squamous histology, where clinical outcomes are still poor.
50. R.S.Herbst, P.Baas, D.-W.Kim, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 2015 [published online 2015 December19]. doi:10.1016/S0140-6736(15)01281-7.•• Anti PD-1/PD-L1 as a valid therapeutic option in second-line setting, especially in squamous histology, where clinical outcomes are still poor.